Amgen Fremont Inc.

Pfizer Corporation

Warner-lambert Company

Sirid-Aimee Kellermann

Mary Haak-Frendscho

Larry L Green

Ian Nevin Foltz

Vahe Bedian

Joseph Edwin Low

Madhav Narasimha Devalaraja

James Leslie Mobley

Wouter Korver

Nicholas Pullen

Elizabeth Molloy

James A Thomson

Arvind Rajpal

Grant Raymond Wickman

Michael Aidan North

Gerald Fries Casperson

Xin Jiang

Dana Dan Hu-Lowe

Wei Liao

Mark A Moffat

Jianying Wang

Shelley Sims Belouski

Karin Kristina Amundson

Shannon Marie Karlicek

Jingchuan Zhang

Wai Leung Liu

Nurten Beyaz-Kavuncu

Caroline Brown

Judith Diaz-Collier

James Arthur Thomson

Mike Yeadon

Isabelle De Mendez

Alison Logan

Nicholas c/o Pfizer Global Research And De Pullen

Elizabeth c/o Pfizer Global Research And D Molloy

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

Antibodies to M-CSF

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.

Antibodies to MAdCAM

The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

Methods of monitoring a human anti-human antibody response and inhibitors thereof

The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.

Reducing the risk of human anti-human antibodies through V gene manipulation

Nucleic acid molecules encoding antibodies to M-CSF

The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.

Anti-IgE antibodies

Growing community of inventors

Menlo Park, CA, United States of America

Sirid-Aimee Kellermann